Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Subchronic toxicity of S-111-S-WB in Sprague Dawley rats.

Mertens JJ, Sved DW, Marit GB, Myers NR, Stetson PL, Murphy SR, Schmit B, Shinohara M, Farr CH.

Int J Toxicol. 2010 Jul;29(4):358-71. doi: 10.1177/1091581810370372. Epub 2010 Jun 2.

PMID:
20519691
2.

Comparison of the toxicokinetic behavior of perfluorohexanoic acid (PFHxA) and nonafluorobutane-1-sulfonic acid (PFBS) in cynomolgus monkeys and rats.

Chengelis CP, Kirkpatrick JB, Myers NR, Shinohara M, Stetson PL, Sved DW.

Reprod Toxicol. 2009 Jun;27(3-4):400-6. doi: 10.1016/j.reprotox.2009.01.013. Epub 2009 Feb 11.

PMID:
19429410
3.

Absorption, tissue distribution, metabolism and elimination of taurine given orally to rats.

Sved DW, Godsey JL, Ledyard SL, Mahoney AP, Stetson PL, Ho S, Myers NR, Resnis P, Renwick AG.

Amino Acids. 2007;32(4):459-66. Epub 2007 Feb 16.

PMID:
17514497
4.
5.

Simultaneous determination of six urinary porphyrins using liquid chromatography-tandem mass spectrometry.

Bu W, Myers N, McCarty JD, O'Neill T, Hollar S, Stetson PL, Sved DW.

J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Jan 15;783(2):411-23.

PMID:
12482484
6.

Rabbit serum paraoxonase 3 (PON3) is a high density lipoprotein-associated lactonase and protects low density lipoprotein against oxidation.

Draganov DI, Stetson PL, Watson CE, Billecke SS, La Du BN.

J Biol Chem. 2000 Oct 27;275(43):33435-42.

7.

Sensitization of 1,3-bis(2-chloroethyl)-1-nitrosourea and cisplatin cytotoxicity by 5-bromo-2'-deoxyuridine in human glioma.

Mancini WR, Glaze ER, Stetson PL, Greenberg HS.

J Pharmacol Exp Ther. 1999 Jun;289(3):1404-9.

8.

Preferential cytotoxicity of cells transduced with cytosine deaminase compared to bystander cells after treatment with 5-flucytosine.

Lawrence TS, Rehemtulla A, Ng EY, Wilson M, Trosko JE, Stetson PL.

Cancer Res. 1998 Jun 15;58(12):2588-93.

9.

Regional pharmacokinetics of 5-fluorouracil in dogs: role of the liver, gastrointestinal tract, and lungs.

Kuan HY, Smith DE, Ensminger WD, Knol JA, DeRemer SJ, Yang Z, Stetson PL.

Cancer Res. 1998 Apr 15;58(8):1688-94.

10.

Steady-state pharmacokinetics of delavirdine in HIV-positive patients: effect on erythromycin breath test.

Cheng CL, Smith DE, Carver PL, Cox SR, Watkins PB, Blake DS, Kauffman CA, Meyer KM, Amidon GL, Stetson PL.

Clin Pharmacol Ther. 1997 May;61(5):531-43.

11.

Regional pharmacokinetics of 5-bromo-2'-deoxyuridine and 5-fluorouracil in dogs: hepatic arterial versus portal venous infusions.

Kuan HY, Smith DE, Ensmiger WD, Knol JA, DeRemer SJ, Yang Z, Stetson PL.

Cancer Res. 1996 Oct 15;56(20):4724-7.

12.

Effect of irradiation on bromodeoxyuridine incorporation in human colon cancer xenografts.

Lawrence TS, Chang EY, Davis MA, Stetson PL, Ensminger WD.

Int J Radiat Oncol Biol Phys. 1996 Feb 1;34(3):617-21.

PMID:
8621286
13.

Incorporation of 5-bromo-2'-deoxyuridine into colorectal liver metastases and liver in patients receiving a 7-day hepatic arterial infusion.

Knol JA, Walker SC, Robertson JM, Yang Z, DeRemer S, Stetson PL, Ensminger WD, Lawrence TS.

Cancer Res. 1995 Sep 1;55(17):3687-91.

14.

Bromodeoxyuridine-mediated radiosensitization in human glioma: the effect of concentration, duration, and fluoropyrimidine modulation.

McLaughlin PW, Lawrence TS, Seabury H, Nguyen N, Stetson PL, Greenberg HS, Mancini WR.

Int J Radiat Oncol Biol Phys. 1994 Oct 15;30(3):601-7.

PMID:
7928491
15.

Kinetics of bromodeoxyuridine elimination from human colon cancer cells in vitro and in vivo.

Lawrence TS, Davis MA, Stetson PL, Maybaum J, Ensminger WD.

Cancer Res. 1994 Jun 1;54(11):2964-8.

16.

Clinical pharmacology of hepatic arterial infusions of 5-bromo-2'-deoxyuridine.

Ensminger WD, Walker SC, Stetson PL, Wagner JG, Knol JA, Lawrence TS, Andrews JC.

Cancer Res. 1994 Apr 15;54(8):2121-4.

17.
18.

Halogenated pyrimidine sensitization of low dose rate irradiation in human malignant glioma.

McLaughlin PW, Mancini WR, Stetson PL, Greenberg HS, Nguyen N, Seabury H, Heidorn DB, Lawrence TS.

Int J Radiat Oncol Biol Phys. 1993 Jul 15;26(4):637-42.

PMID:
8330994
19.

Mutual kinetic interaction between 5-fluorouracil and bromodeoxyuridine or iododeoxyuridine in dogs.

Smith DE, Brenner DE, Knutsen CA, Deremer SJ, Terrio PA, Johnson NJ, Stetson PL, Ensminger WD.

Drug Metab Dispos. 1993 Mar-Apr;21(2):277-83.

PMID:
8097697
20.

The potential superiority of bromodeoxyuridine to iododeoxyuridine as a radiation sensitizer in the treatment of colorectal cancer.

Lawrence TS, Davis MA, Maybaum J, Mukhopadhyay SK, Stetson PL, Normolle DP, McKeever PE, Ensminger WD.

Cancer Res. 1992 Jul 1;52(13):3698-704.

21.

Cyclosporine metabolism by P450IIIA in rat enterocytes--another determinant of oral bioavailability?

Kolars JC, Stetson PL, Rush BD, Ruwart MJ, Schmiedlin-Ren P, Duell EA, Voorhees JJ, Watkins PB.

Transplantation. 1992 Mar;53(3):596-602.

PMID:
1549853
22.

Modulation of iododeoxyuridine-mediated radiosensitization by 5-fluorouracil in human colon cancer cells.

Lawrence TS, Davis MA, Maybaum J, Stetson PL, Ensminger WD.

Int J Radiat Oncol Biol Phys. 1992;22(3):499-503.

PMID:
1735687
23.

Biochemical modulation of 5-bromo-2'-deoxyuridine and 5-iodo-2'-deoxyuridine incorporation into DNA in VX2 tumor-bearing rabbits.

Stetson PL, Normolle DP, Knol JA, Johnson NJ, Yang ZM, Sakmar E, Prieskorn D, Terrio P, Knutsen CA, Ensminger WD.

J Natl Cancer Inst. 1991 Nov 20;83(22):1659-67.

PMID:
1836238
24.

Fluorodeoxyuridine-mediated modulation of iododeoxyuridine incorporation and radiosensitization in human colon cancer cells in vitro and in vivo.

Lawrence TS, Davis MA, McKeever PE, Maybaum J, Stetson PL, Normolle DP, Ensminger WD.

Cancer Res. 1991 Aug 1;51(15):3900-5.

25.

Divergent patterns of incorporation of bromodeoxyuridine and iododeoxyuridine in human colorectal tumor cell lines.

Maybaum J, Burton EC, Shelton DA, Jing HW, Dusenbury CE, Ensminger WD, Stetson PL.

Biochem Pharmacol. 1991 Jun 21;42(1):131-7.

26.

Variability of 5-bromo-2'-deoxyuridine incorporation into DNA of human glioma cell lines and modulation with fluoropyrimidines.

Mancini WR, Stetson PL, Lawrence TS, Wagner JG, Greenberg HS, Ensminger WD.

Cancer Res. 1991 Feb 1;51(3):870-4.

27.
28.

Intra-arterial bromodeoxyuridine radiosensitization of malignant gliomas.

Hegarty TJ, Thornton AF, Diaz RF, Chandler WF, Ensminger WD, Junck L, Page MA, Gebarski SS, Hood TW, Stetson PL, et al.

Int J Radiat Oncol Biol Phys. 1990 Aug;19(2):421-8.

PMID:
2168357
29.

The dependence of halogenated pyrimidine incorporation and radiosensitization on the duration of drug exposure.

Lawrence TS, Davis MA, Maybaum J, Stetson PL, Ensminger WD.

Int J Radiat Oncol Biol Phys. 1990 Jun;18(6):1393-8.

PMID:
2370189
30.

Pharmacodynamics of 5-iodo-2'-deoxyuridine in VX2 tumor-bearing rabbits.

Stetson PL, Yang ZM, Ensminger WD.

J Natl Cancer Inst. 1989 Dec 20;81(24):1925-6. No abstract available.

PMID:
2593171
31.

5-Bromo-2'-deoxyuridine incorporation into DNA in hepatic VX2 tumor-bearing rabbits.

Knol JA, Stetson PL, Wagner JG, Johnson NJ, Yang ZM, Prieskorn D, Terrio P, Knutsen CA, Ensminger WD.

J Surg Res. 1989 Aug;47(2):112-6.

32.

Stability of trimetrexate, a new non-classical antifolate, in infusion solutions.

Stetson PL, Shukla UA, Ensminger WD.

J Chromatogr. 1989 Feb 17;464(1):163-71.

PMID:
2523896
33.

Steady-state arterial and hepatic venous plasma concentrations of 5-bromo-2'-deoxyuridine and 5-iodo-2'-deoxyuridine in animals--drugs which are subject to both splanchnic and extra-splanchnic elimination.

Wagner JG, Stetson PL, Knol JA, Andrews JC, Walker-Andrews S, Knutsen CA, Johnson N, Prieskorn D, Terrio P, Yang Z, et al.

Sel Cancer Ther. 1989 Winter;5(4):193-203.

PMID:
2623384
34.

Response of human HT-29 colorectal tumor cells to extended exposure to bromodeoxyuridine.

Maybaum J, Hafner MS, Burton EC, Stetson PL, Ensminger WD, Rogers CE.

Cancer Chemother Pharmacol. 1989;25(1):45-50.

35.

Tissue-specific pharmacodynamics of 5-bromo-2'-deoxyuridine incorporation into DNA in VX2 tumor-bearing rabbits.

Stetson PL, Maybaum J, Wagner JG, Averill DR, Wollner IS, Knol JA, Johnson NJ, Yang ZM, Preiskorn D, Smith P, et al.

Cancer Res. 1988 Dec 1;48(23):6900-5.

36.

Intra-arterial bromodeoxyuridine radiosensitization and radiation in treatment of malignant astrocytomas.

Greenberg HS, Chandler WF, Diaz RF, Ensminger WD, Junck L, Page MA, Gebarski SS, McKeever P, Hood TW, Stetson PL, et al.

J Neurosurg. 1988 Oct;69(4):500-5.

PMID:
3047341
37.

Dynamics of bromodeoxyuridine incorporation into DNA of squamous carcinoma cells during mid and late logarithmic growth.

Shapira A, Wagner JG, Wollner IS, Maybaum J, Stetson PL, Ensminger WD, Carey TE.

Pharm Res. 1988 Aug;5(8):518-22.

38.

Effects of hepatic arterial yttrium-90 microsphere administration alone and combined with regional bromodeoxyuridine infusion in dogs.

Wollner IS, Knutsen CA, Ullrich KA, Chrisp CE, Juni JE, Andrews JC, Tuscan MJ, Stetson PL, Ensminger WD.

Cancer Res. 1987 Jun 15;47(12):3285-90.

39.
40.
41.

A dog model using an implanted system for protracted hepatic arterial chemotherapy.

Wollner IS, Knutsen CA, Ullrich KA, Niederhuber JE, Crudup JW, Juni JE, Warber SL, Gyves J, Stetson PL, Ensminger WD.

J Surg Res. 1986 Nov;41(5):510-7.

42.

Steady-state nonlinear pharmacokinetics of 5-fluorouracil during hepatic arterial and intravenous infusions in cancer patients.

Wagner JG, Gyves JW, Stetson PL, Walker-Andrews SC, Wollner IS, Cochran MK, Ensminger WD.

Cancer Res. 1986 Mar;46(3):1499-506.

43.
44.

Sensitive high-performance liquid chromatographic method for the determination of 5-fluorouracil in plasma.

Stetson PL, Shukla UA, Ensminger WD.

J Chromatogr. 1985 Nov 8;344:385-90. No abstract available.

45.

Rapid gas-liquid chromatographic method for plasma verapamil level determination.

Shukla UA, Stetson PL, Ensminger WD.

J Chromatogr. 1985 Aug 9;342(2):406-10. No abstract available.

46.

High-performance liquid chromatographic method for the determination of bromodeoxyuridine and its major metabolite, bromouracil, in biological fluids.

Stetson PL, Shukla UA, Amin PR, Ensminger WD.

J Chromatogr. 1985 May 31;341(1):217-22. No abstract available.

47.
48.

BCNU solubility and toxicity in the treatment of malignant astrocytomas.

Layton PB, Greenberg HS, Stetson PL, Ensminger WD, Gyves JW.

J Neurosurg. 1984 Jun;60(6):1134-7.

PMID:
6726357
49.

Dopamine beta-Hydroxylation in diabetes ane diabetic autonomic neuropathy.

Hoeldtke RD, Stetson PL.

Biochem Med. 1981 Aug;26(1):67-76. No abstract available.

50.

Specific and sensitive assays for digoxin in plasma, urine and heart tissue.

Morais JA, Zlotecki RA, Sakmar E, Stetson PL, Wagner JG.

Res Commun Chem Pathol Pharmacol. 1981 Feb;31(2):285-98.

PMID:
7221184

Supplemental Content

Loading ...
Support Center